Monoclonal Gammopathy Of Undetermined Significance (MGUS)
MGUS is a premalignant clonal plasma cell disorder characterized by a serum monoclonal protein <3 g/dL, bone marrow plasma cells <10%, and absence of end-organ damage attributable to the proliferative process.
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Monoclonal Gammopathy of Undetermined Significance (MGUS) is a premalignant clonal plasma cell (or lymphoplasmacytic) disorder characterised by the presence of a monoclonal immunoglobulin (M-protein / paraprotein) in the serum, without evidence of an underlying B-cell lymphoproliferative disorder and without end-organ damage.
Breaking down the name:
- Monoclonal = derived from a single clone of B-lymphocytes / plasma cells (i.e., all the immunoglobulin molecules produced are identical)
- Gammopathy = "gamma" refers to the gamma-globulin fraction on serum protein electrophoresis (where immunoglobulins migrate); "-pathy" = disease/disorder — so a disorder of the gamma-globulins
- Undetermined Significance = we don't yet know whether this will remain benign or progress to a malignant condition; it is a state of clinical uncertainty
"MGUS refers to paraproteinaemia not related with underlying disease, e.g. MM/SMM, lymphoma, amyloidosis, WM" [2]
Key Conceptual Point
MGUS sits at the very beginning of the plasma cell dyscrasia spectrum. Think of it as the earliest, pre-symptomatic foothold of a clonal plasma cell population. The critical clinical question is always: will this progress? Because MGUS itself, by definition, causes no organ damage and requires no treatment — only surveillance.
Formal Diagnostic Definition (IMWG Criteria)
The formal definition of having MGUS is: [1][3]
- Presence of paraprotein of less than 30 g/L (< 3 g/dL) — AND
- Bone marrow plasma cells of < 10%, without
- Evidence of B-cell lymphoproliferative disorder — AND
- Absence of organ damage (i.e., no CRAB features: hyperCalcaemia, Renal insufficiency, Anaemia, Bone lesions; and no amyloidosis-related organ damage)
"Presence of paraprotein of less than 30g/L AND bone marrow plasma cells of less than 10% without any evidence of B cell lymphoproliferative disorder AND absence of organ damage" [1]
MGUS vs Smouldering Myeloma vs Active MM
These three exist on a continuum / spectrum. The key differentiators:
| Feature | MGUS | Smouldering MM (SMM) | Active MM |
|---|---|---|---|
| M-protein | < 3 g/dL | ≥ 3 g/dL and/or | Any level |
| BM plasma cells | < 10% | 10–60% | ≥ 10% (or biopsy-proven plasmacytoma) |
| End-organ damage (CRAB) or myeloma-defining events (MDEs) | Absent | Absent | Present |
| Treatment required? | No (monitor) | No (monitor; some high-risk may enter trials) | Yes |
2. Epidemiology
MGUS is very common — approximately 5% of the population above 50 years of age [1][3]
More granular prevalence data [2]:
- Found in 1–2% of all adults
- Prevalence 3.2% in ≥ 50 years
- 5.3% in ≥ 70 years
- 7.5% in ≥ 85 years
This makes MGUS far more common than multiple myeloma itself. The vast majority of MGUS patients will never develop myeloma — but because the denominator is so large, MGUS remains the obligate precursor state for virtually all cases of MM.
- Age: prevalence increases with age (as above) — median age at diagnosis is 65–70 years [2]
- Sex: M > F (4.0% vs 2.7% in ≥ 50 years) [2]
- Ethnicity: African Americans have approximately 2–3× higher prevalence than Caucasians; Asian populations (including Hong Kong Chinese) have somewhat lower rates than Caucasians, though data are limited. The condition is still common in HK's ageing population.
- Family: 2.8× increased prevalence in first-degree relatives of MGUS patients [2]
- HK has a rapidly ageing population → the absolute number of MGUS cases detected incidentally is increasing
- MGUS is a common incidental finding when investigating elevated ESR, abnormal globulin levels, or unexplained proteinuria in elderly patients presenting to medical clinics
- Myeloma (and by extension, monoclonal gammopathy) is listed as a cause of CKD in HK clinical practice [4]
3. Anatomy and Function: The Plasma Cell and Immunoglobulin System
To understand MGUS, you need to understand where plasma cells come from and what immunoglobulins are.
- Plasma cells are terminally differentiated B-lymphocytes whose sole function is to secrete large quantities of immunoglobulin (antibody)
- Each plasma cell produces immunoglobulin of a single specificity — i.e., one heavy chain class (IgG, IgA, IgM, IgD, IgE) and one light chain type (kappa κ or lambda λ)
- Normally, the immune system is polyclonal: thousands of different plasma cell clones each producing different antibodies → the gamma-globulin band on SPEP is a broad smear
An immunoglobulin molecule consists of:
- 2 heavy chains (determining the class: γ = IgG, α = IgA, μ = IgM, δ = IgD, ε = IgE)
- 2 light chains (either κ or λ)
- Held together by disulfide bonds
In MGUS, a single clone expands and produces a monoclonal immunoglobulin — this appears as a sharp, discrete spike (M-spike) on serum protein electrophoresis, rather than the normal broad polyclonal band.
- Plasma cells produce light chains in slight excess of heavy chains
- These excess light chains circulate as free light chains (FLC) and are filtered by the kidneys (MW ~22 kDa for monomers, ~44 kDa for dimers)
- When FLC are present in urine, they are called Bence Jones protein
- The normal serum free κ:λ ratio is approximately 0.26–1.65; an abnormal ratio (< 0.26 or > 1.65) suggests monoclonal origin [5]
4. Aetiology and Risk Factors
The exact cause is unknown, but the prevailing understanding is:
- Somatic mutations accumulate in a post-germinal-centre B-cell or long-lived plasma cell over a lifetime, giving it a survival and/or proliferative advantage
- The abnormal clone expands within the bone marrow niche
- At the MGUS stage, the clone is small, proliferating slowly, and does not cause tissue damage
- Additional "hits" (further mutations, microenvironmental changes) are required for progression to SMM or MM
| Risk Factor | Mechanism / Explanation |
|---|---|
| Age | Accumulation of somatic mutations over time; declining immune surveillance |
| Male sex | Unclear; possibly hormonal or occupational exposures |
| African ancestry | Genetic predisposition (higher prevalence even after adjusting for socioeconomic factors) |
| Family history | 2.8× in first-degree relatives — suggests heritable genetic susceptibility [2] |
| Immunosuppression | HIV, post-transplant immunosuppression → reduced immune surveillance of clonal expansions |
| Chronic antigenic stimulation | Autoimmune diseases (e.g., RA, SLE), chronic infections → persistent B-cell activation may predispose |
| Pesticide / herbicide exposure | Epidemiological association (agricultural workers) |
| Obesity | Adipokine-mediated chronic inflammation may support clonal expansion |
| Radiation exposure | Historical data from atomic bomb survivors |
The risk of progression from MGUS to myeloma is ~1% per year [1][3]
Risk factors for progression include: [1][3]
| Risk Factor | Explanation |
|---|---|
| Size of paraprotein | Small = lower chance of progression; larger M-spike (approaching 3 g/dL) = higher risk |
| Type of paraprotein | Non-IgG types (IgA, IgM) carry higher risk than IgG |
| Light chain ratio (serum FLC ratio) | Abnormal κ:λ ratio indicates a more established clone |
| Rate of rise in paraprotein | An evolving (rising) M-protein suggests more aggressive biology |
| Bone marrow morphology | Higher percentage of plasma cells, abnormal immunophenotype |
"Risk of progression to myeloma: Size of paraprotein, Type of paraprotein, Light chain ratio, Rate of rise in paraprotein, Bone marrow morphology" [1]
The Mayo Clinic risk stratification model (2005, updated) uses three factors to stratify MGUS risk:
- M-protein ≥ 1.5 g/dL
- Non-IgG isotype
- Abnormal serum FLC ratio
| Risk Group | Number of Factors | 20-year Progression Risk |
|---|---|---|
| Low | 0 | ~5% |
| Low-intermediate | 1 | ~21% |
| High-intermediate | 2 | ~37% |
| High | 3 | ~58% |
5. Pathophysiology
In MGUS, a clone of plasma cells (or lymphoplasmacytic cells, in IgM MGUS) has acquired mutations that allow it to:
- Self-renew more effectively than normal plasma cells
- Resist apoptosis (e.g., via overexpression of BCL-2 family members)
- Interact with the bone marrow microenvironment (stromal cells, cytokines like IL-6)
However, the clone is still small (< 10% of BM cellularity) and has not acquired the additional genetic "hits" needed to cause organ damage.
Even at the MGUS stage, clonal plasma cells harbour cytogenetic abnormalities:
- Trisomies (hyperdiploidy) — odd-numbered chromosomes
- IgH translocations: t(11;14), t(4;14), t(14;16) — these are the same translocations seen in MM, just present earlier
- The accumulation of additional mutations (e.g., RAS mutations, MYC translocations, del(17p) with TP53 loss) is what drives progression from MGUS → SMM → MM
At the MGUS stage:
- The tumour burden is too low to cause significant bone destruction (osteoclast activation requires a critical mass of myeloma cells secreting RANKL, DKK1, MIP-1α)
- The amount of monoclonal light chain produced is insufficient to cause cast nephropathy (myeloma kidney) in most cases
- The bone marrow is not sufficiently infiltrated to suppress normal haematopoiesis → no anaemia from marrow failure
- Hypercalcaemia does not occur because osteolysis is minimal
Although MGUS is defined by the absence of end-organ damage, the circulating M-protein can still cause:
-
Laboratory artifacts [2]:
- Spuriously low HDL-C level
- High bilirubin level
- Altered inorganic phosphate level
- Apparent high calcium (paraproteins bind calcium, elevating total but not ionised calcium) [6]
-
Elevated ESR: Monoclonal immunoglobulins cause rouleaux formation → markedly elevated ESR (often > 100 mm/hr) even without infection or inflammation
-
Reversed A:G ratio: ↑ globulin fraction (from the M-protein) with normal or slightly low albumin → reversed albumin-to-globulin ratio [2]
-
Immunoparesis: Even in MGUS, the polyclonal (normal) immunoglobulins may be suppressed — this is because the clonal plasma cells crowd out normal plasma cells and/or immunoregulatory mechanisms suppress them. This is more prominent in higher-risk MGUS.
Factitious Hypercalcaemia in MGUS
Paraproteinaemia with ↑IgM (or other isotypes) can cause factitious ↑Ca due to direct interference [6]. The M-protein binds calcium in vitro, raising the total calcium while the ionised calcium remains normal. Always check ionised calcium in patients with paraproteinaemia and apparent hypercalcaemia before assuming true hypercalcaemia! If the ionised calcium is normal, there is no real hypercalcaemia — it is a lab artifact.
6. Classification of MGUS
MGUS is not a single entity — it is classified into subtypes based on the immunoglobulin isotype of the M-protein, which determines the cell of origin and the diseases it may progress to.
- M-protein is IgM (~17%) [2]
- Cell of origin: clonal lymphoplasmacytic cell (a cell intermediate between a B-lymphocyte and a plasma cell)
- Progression risk: ~2% per year in the first 10 years, then ~1% per year [2]
- Progresses to: Waldenström macroglobulinaemia (WM), AL amyloidosis, NHL, CLL [2]
- IgM MGUS is biologically more closely related to lymphoma than to myeloma
- No intact monoclonal immunoglobulin detectable on SPEP
- Only an abnormal serum FLC ratio with elevated monoclonal free light chains
- Progression risk: ~0.3% per year [2]
- Progresses to: idiopathic Bence Jones proteinuria (i.e., light-chain SMM), light-chain myeloma, AL amyloidosis
- ~3% of cases [2]
- Two distinct M-proteins (either two different heavy chains, or same heavy chain with different light chains)
- Managed similarly; each clone assessed independently
| Subtype | Isotype | Prevalence | Cell of Origin | Annual Progression Risk | Progresses to |
|---|---|---|---|---|---|
| Non-IgM MGUS | IgG (69%), IgA (11%) | Most common | Plasma cell | 0.8%/year | MM, plasmacytoma, AL amyloidosis |
| IgM MGUS | IgM (17%) | Second most common | Lymphoplasmacytic cell | 2%/year (first 10y) → 1%/year | WM, NHL, CLL, AL amyloidosis |
| LC-MGUS | FLC only | Less common | Plasma cell | 0.3%/year | LC-MM, AL amyloidosis |
| Biclonal | Two M-proteins | ~3% | Variable | Variable | Depends on constituent clones |
MGUS sits within a broader spectrum of plasma cell dyscrasias: [5]
"Stage 1: MGUS → Stage 2: Smouldering myeloma → Stage 3: Myeloma (multiple myeloma). Myeloma is a spectrum/timeline, and multiple myeloma is considered to be the 'end-of-the-spectrum' manifestation of plasma cell dyscrasia." [3]
"Some patients can convert from MGUS back to normal" [3] — meaning the clone can occasionally die out spontaneously, though this is uncommon.
What Determines Progression?
The "multi-hit" model of myelomagenesis:
- Initiating events (present even in MGUS): IgH translocations or hyperdiploidy
- Early progression events (MGUS → SMM): RAS mutations, NF-κB pathway activation, epigenetic changes
- Late progression events (SMM → MM): MYC translocations, del(17p)/TP53 loss, 1q gain, bone marrow microenvironment remodelling (angiogenesis, osteoclast activation, immune evasion)
8. Clinical Features
By definition, MGUS is asymptomatic [2]. Patients should have no symptoms attributable to the monoclonal proliferation.
If a patient has symptoms, you must consider whether they have progressed beyond MGUS (to SMM, MM, WM, or amyloidosis) or whether the symptoms are from a separate condition.
However, there are some nuanced clinical scenarios:
| Finding | Explanation |
|---|---|
| Asymptomatic | The hallmark. MGUS is almost always an incidental finding during workup for another condition |
| Peripheral neuropathy | ~5% of MGUS patients develop a distal sensorimotor polyneuropathy, most commonly associated with IgM MGUS (anti-MAG antibody neuropathy). This is technically "MGUS with clinical significance" but by convention still called MGUS unless another diagnosis is made |
| Increased infection susceptibility | Due to immunoparesis (suppression of normal polyclonal immunoglobulins). Subtle but real |
"Only multiple myeloma patients will be symptomatic with organ involvement → requires treatment. Other forms do not require treatment → require monitoring" [3]
Physical examination is typically normal in MGUS.
If any of the following signs are present, you should be concerned about progression or an alternative diagnosis:
| Sign | What it suggests | Pathophysiological basis |
|---|---|---|
| Pallor | Anaemia → possible progression to MM (marrow infiltration) or AL amyloidosis | Clonal plasma cells replacing normal haematopoietic tissue |
| Bone tenderness | Lytic bone disease → active MM | Osteoclast activation by myeloma cell-derived RANKL, DKK1, MIP-1α |
| Hepatosplenomegaly | Extramedullary disease (rare in MGUS); consider WM, lymphoma, amyloidosis | Infiltration by malignant cells or amyloid deposition |
| Macroglossia, periorbital purpura, carpal tunnel | AL amyloidosis | Light chain amyloid fibrils depositing in soft tissues |
| Peripheral neuropathy signs | IgM-related anti-MAG neuropathy; or AL amyloid neuropathy | Autoantibody against myelin-associated glycoprotein; or amyloid deposition in nerves |
| Skin changes | Rarely, MGUS-associated conditions (e.g., scleromyxoedema, pyoderma gangrenosum, xanthoma) | Paraprotein deposition in skin |
| Rouleaux formation on PBS | Not a bedside sign but a laboratory sign — RBCs stack like coins | M-protein increases serum viscosity and bridges RBCs → rouleaux. Non-specific, indicates ↑ protein level [2] |
The Crucial Clinical Question
When you find an M-protein, the most important question is: "Is this just MGUS, or is there an underlying disease?" You must actively exclude:
MGUS is almost always found incidentally during investigation of:
- Elevated ESR (very common reason for discovery — the M-protein causes rouleaux → markedly ↑ ESR)
- Abnormal total protein / reversed A:G ratio on routine bloods
- Unexplained proteinuria (light chains in urine)
- Workup for anaemia, bone pain, or renal dysfunction (where MM was suspected but criteria not met)
- Unexplained peripheral neuropathy
- Hypercalcaemia workup (where factitious hypercalcaemia due to protein binding is identified)
Although MGUS is defined as "undetermined significance," emerging evidence shows that MGUS patients have:
- ↑ Risk of osteoporosis and fractures — even without lytic lesions; possibly due to low-level osteoclast activation or cytokine effects
- ↑ Risk of venous thromboembolism — mechanism unclear; possibly related to paraprotein-induced hypercoagulability
- ↑ Risk of infections — due to immunoparesis
- Slightly decreased lifespan: 8.1 years median survival vs 12.4 years in matched controls [2], mainly because of the median age at diagnosis (65–70 years) and the 25–30% lifetime risk of progression
- Associations with autoimmune diseases and peripheral neuropathy (especially IgM MGUS → anti-MAG neuropathy)
- Renal disease: Monoclonal gammopathy of renal significance (MGRS) is a recently recognised entity where the M-protein causes renal damage (e.g., light chain deposition disease, membranoproliferative GN, C3 glomerulopathy) despite not meeting criteria for MM. This is a paradigm shift — the "undetermined significance" becomes renal significance.
MGRS — Monoclonal Gammopathy of Renal Significance
MGRS is a crucial modern concept. These patients have a small clone (meeting MGUS or SMM criteria by marrow involvement) but the monoclonal protein is directly causing kidney damage. Unlike MGUS, these patients require treatment of the clone to halt renal progression, even though they don't have "myeloma." Think of it as: the clone is small but the protein is toxic to the kidney. Key renal lesions include: proliferative GN with monoclonal Ig deposits, C3 glomerulopathy, immunotactoid glomerulopathy, light chain proximal tubulopathy (Fanconi syndrome), and fibrillary GN.
When an M-protein is detected, the following baseline investigations are needed to confirm MGUS and exclude a more advanced disease:
| Investigation | Purpose |
|---|---|
| Serum protein electrophoresis (SPEP) + immunofixation | Detect and quantify M-protein; identify isotype (IgG, IgA, IgM) and light chain type (κ or λ) |
| Serum free light chains (sFLC) + κ:λ ratio | Detect light-chain-only disease; abnormal ratio suggests monoclonal origin |
| 24-hour urine for Bence Jones protein | Detect monoclonal FLC in urine |
| CBC / PBS | Exclude cytopenias (anaemia, thrombocytopenia); look for rouleaux |
| Renal function (creatinine, eGFR) | Exclude renal impairment |
| Calcium (ionised preferred) | Exclude hypercalcaemia |
| Serum albumin | Prognostic; low albumin may suggest amyloidosis or more advanced disease |
| LDH, β2-microglobulin | Prognostic markers (elevated in more advanced disease) |
| Quantitative immunoglobulins | Assess for immunoparesis (suppression of uninvolved Ig classes) |
| Bone marrow biopsy | Confirm < 10% clonal plasma cells; cytogenetics/FISH |
| Skeletal survey / low-dose whole-body CT | Exclude lytic bone lesions |
High Yield Summary
- MGUS is the most common plasma cell dyscrasia — ~5% of people > 50 years; M > F; prevalence ↑ with age
- Definition: M-protein < 3 g/dL, BM plasma cells < 10%, no B-cell lymphoproliferative disorder, no end-organ damage (CRAB)
- Three main subtypes: Non-IgM MGUS (most common, IgG > IgA), IgM MGUS (risk of WM/lymphoma), LC-MGUS
- Progression risk: Non-IgM ~0.8%/year, IgM ~2%/year, LC ~0.3%/year
- Risk factors for progression: Size of M-protein, type (non-IgG worse), abnormal FLC ratio, rate of rise, BM morphology
- By definition asymptomatic — always an incidental finding; any CRAB symptom = exclude myeloma
- Most important DDx to exclude: AL amyloidosis (especially if suggestive symptoms), MM, WM
- Lab artifacts: Elevated ESR, reversed A:G ratio, factitious hypercalcaemia (check ionised Ca), interference with HDL-C, phosphate, bilirubin assays
- Management: Monitoring only — no treatment; regular follow-up to detect progression
- MGRS is a newer concept where the small clone causes direct renal damage → requires treatment despite not meeting MM criteria
Active Recall - MGUS
[1] Lecture slides: GC 030. An old man with bone pain and anaemia.pdf (MGUS slide) [2] Senior notes: Ryan Ho Haemtology.pdf (Section 3.6.2 Monoclonal Gammopathy of Undetermined Significance) [3] Senior notes: Block A - An old man with bone pain and anaemia_ multiple myeloma; monoclonal gammopathy.pdf (Development of myeloma / MGUS section) [4] Senior notes: Block A - Chronic Kidney Disease and its Complications.pdf (Causes of CKD) [5] Senior notes: Maksim Medicine Notes.pdf (Spectrum of plasma cell dyscrasias, FLC ratio) [6] Senior notes: Ryan Ho Chemical Path.pdf (Paraproteinaemia and factitious hypercalcaemia)
Differential Diagnosis of MGUS
The differential diagnosis of MGUS operates on two distinct clinical axes. You need to think about both simultaneously:
- Axis 1 — "I've found an M-protein. What could be causing it?" → i.e., what is the differential diagnosis of a monoclonal gammopathy in general? MGUS is only one possibility.
- Axis 2 — "The patient has MGUS. What might it progress to or mimic?" → i.e., what conditions must I actively exclude before I can safely label someone as "MGUS"?
These two axes overlap substantially, but framing them separately helps you think systematically.
When you detect an M-protein on serum protein electrophoresis (SPEP), the differential is the entire spectrum of plasma cell dyscrasias and lymphoproliferative disorders plus some reactive/benign causes.
The spectrum of diseases for monoclonal gammopathy includes: [7]
Complete Differential of Monoclonal Gammopathy
| Category | Condition | Key Distinguishing Features |
|---|---|---|
| Plasma cell neoplasms | MGUS | M-protein < 3 g/dL, BM plasma cells < 10%, no end-organ damage [1][3] |
| Smouldering MM (SMM) | M-protein ≥ 3 g/dL and/or BM plasma cells 10–60%, but no CRAB/MDE; 10%/year progression in first 5 years [3] | |
| Active Multiple Myeloma | BM plasma cells ≥ 10% plus CRAB features or myeloma-defining events (see below) | |
| Solitary plasmacytoma | Single bone or soft-tissue mass of clonal plasma cells; no systemic disease | |
| Plasma cell leukaemia | Circulating plasma cells > 2 × 10⁹/L or > 20% of WBC differential; aggressive | |
| Lymphoproliferative diseases | Waldenström macroglobulinaemia (WM) | IgM paraproteinaemia + BM shows lymphoplasmacytoid cells [5]; hyperviscosity symptoms |
| CLL | Clonal mature B-lymphocytes; small M-protein in ~5% of CLL cases | |
| Indolent B-cell lymphoma (e.g., marginal zone, follicular) | May secrete small amounts of M-protein | |
| Immunoglobulin deposition diseases | AL amyloidosis | Organ deposition of amyloid proteins consisting of monoclonal light chains [5]; macroglossia, nephrotic syndrome, cardiomyopathy, neuropathy |
| Light chain deposition disease (LCDD) | Organ deposition of light chains that do not form amyloid fibrils [5]; often renal (nodular glomerulosclerosis) | |
| Heavy chain deposition disease | Rare; renal and systemic involvement | |
| Other | POEMS syndrome | Polyneuropathy, Organomegaly, Endocrinopathy, M-protein (usually λ light chain), Skin changes [5] |
| Heavy chain diseases (α, γ, μ) | Rare; secrete truncated heavy chains without light chains | |
| Monoclonal gammopathy of renal significance (MGRS) | Clone meets MGUS/SMM criteria by size, but M-protein causes direct renal damage | |
| Reactive / transient | Transient monoclonal gammopathy | Post-infection, post-transplant immune reconstitution; usually disappears spontaneously |
"Spectrum of diseases for monoclonal gammopathy: Plasma cell dyscrasia (MGUS → SMM → MM → Extramedullary MM / Plasma cell leukaemia; Plasmacytoma); Lymphoproliferative disease (CLL, Indolent B-cell lymphoma, Waldenström macroglobulinaemia); Amyloid light chain amyloidosis (AL amyloidosis / Primary amyloidosis)" [7]
High Yield — GC Lecture Slide
"AL amyloidosis is a DDx if patient has suggestive symptoms" [1]. This is the single most important differential to exclude when you diagnose MGUS. Even a small clone can produce enough light chains to cause fatal amyloid deposition in the heart, kidneys, or nerves. If the patient has any suggestive symptoms (unexplained heart failure with preserved EF, nephrotic-range proteinuria, peripheral/autonomic neuropathy, macroglossia, periorbital purpura), you must pursue tissue biopsy with Congo red staining.
Axis 2: Conditions to Actively Exclude Before Labelling "MGUS"
The label "MGUS" is essentially a diagnosis of exclusion. You are saying: "I have found a monoclonal protein, but I have excluded every condition that could explain it." The key conditions you must rule out, and why:
Why? Because MM requires immediate treatment, while MGUS requires only monitoring. The distinction is entirely based on the presence or absence of CRAB criteria and myeloma-defining events (MDEs).
"Only multiple myeloma patients will be symptomatic with organ involvement → requires treatment. Other forms do not require treatment → require monitoring." [3]
CRAB criteria (end-organ damage):
- C = Calcium elevation (> 0.25 mmol/L above upper limit of normal, or > 2.75 mmol/L)
- R = Renal insufficiency (creatinine > 177 μmol/L or eGFR < 40)
- A = Anaemia (Hb < 100 g/L or > 20 g/L below lower limit of normal)
- B = Bone lesions (lytic lesions on skeletal survey, CT, or PET-CT)
Myeloma-defining events (MDEs) (IMWG 2014 — even without CRAB, these warrant treatment):
- BM clonal plasma cells ≥ 60%
- Serum FLC ratio ≥ 100 (involved:uninvolved)
-
1 focal lesion on MRI (≥ 5 mm each)
The haematology lecture case beautifully illustrates a presentation that is not MGUS but active MM: a 65-year-old with pathological fracture, pallor, dehydration, Hb 9.3, Ca 3.3, osteolytic lesions, IgG 6300 with suppressed IgA and IgM, and SPE/immunofixation confirming monoclonal IgG [8] — this patient has CRAB features (hypercalcaemia, anaemia, bone lesions) and therefore has active MM, not MGUS.
Why? SMM has a much higher progression risk than MGUS (10%/year in the first 5 years [3]) and requires closer monitoring (some high-risk SMM patients may even be considered for early intervention in clinical trials).
Distinguished from MGUS by:
- M-protein ≥ 3 g/dL and/or BM plasma cells 10–60%
- But still no CRAB/MDE → hence "smouldering" (not yet active)
"Stage 2: Smouldering myeloma — Patient has the distinct feature of abnormal proliferation of clonal plasma cells BUT is asymptomatic, and does not present with any signs of end-organ damage (CRAB)" [3]
"AL amyloidosis is a DDx if patient has suggestive symptoms" [1]
Why is this so important? Because:
- AL amyloidosis can occur with a very small clone — the BM plasma cells may be < 10% and the M-protein < 3 g/dL (i.e., meeting MGUS criteria by tumour burden)
- But the light chains are directly toxic — they misfold into amyloid fibrils and deposit in organs
- Untreated cardiac AL amyloidosis has a median survival of ~6 months
- You can miss it if you only look at the clone size and don't assess for organ deposition
Red flags for AL amyloidosis in a patient labelled "MGUS":
- Unexplained heart failure (especially HFpEF with thick walls but low voltages on ECG — "Small complex / Low QRS voltages on ECG, with a very thickened LV wall → CLASSICAL FOR AMYLOIDOSIS" [9])
- Nephrotic-range proteinuria ("Primary amyloidosis and light chain deposition disease are associated with a monoclonal gammopathy" [10])
- Peripheral/autonomic neuropathy (postural hypotension, early satiety)
- Macroglossia, periorbital purpura, easy bruising (factor X deficiency)
- Carpal tunnel syndrome (bilateral)
Diagnosis requires tissue biopsy → Congo red stain → apple-green birefringence under polarised light. Abdominal fat pad aspirate is the least invasive screening site (~80% sensitivity).
Only relevant for IgM MGUS. WM is defined by:
- IgM paraproteinaemia + BM infiltration by lymphoplasmacytoid cells [5]
- Symptoms: hyperviscosity (blurred vision, headaches, mucosal bleeding), lymphadenopathy, hepatosplenomegaly, cytopenias
-
95% harbour the MYD88 L265P mutation (useful diagnostically)
IgM MGUS has a 2%/year risk of progression in the first 10 years, then ~1%/year → can progress to WM, AL amyloidosis, NHL, CLL [2]
- Organ deposition of light chains that do not form amyloid fibrils [5]
- Unlike AL amyloidosis, deposits are granular, Congo red negative
- Renal presentation: nephrotic syndrome + renal insufficiency; biopsy shows nodular glomerulosclerosis (can mimic diabetic nephropathy histologically)
- "Differential diagnosis includes: Light and heavy chain deposition disease — complication of monoclonal gammopathy" [11]
- The clone is small (meeting MGUS criteria by size), but the monoclonal protein causes direct renal pathology
- Renal lesions include: proliferative GN with monoclonal Ig deposits, C3 glomerulopathy, immunotactoid GN, light chain proximal tubulopathy (acquired Fanconi syndrome), fibrillary GN, type I cryoglobulinaemic GN
- Other renal diseases associated with monoclonal light chains: Amyloidosis (AL type), Light chain deposition disease, Light chain proximal tubulopathy, Type I cryoglobulinaemic glomerulonephritis [12]
- Clinically important because treatment of the clone is needed to prevent progressive renal damage, unlike true MGUS
- Low-grade B-cell lymphomas (e.g., marginal zone lymphoma, follicular lymphoma) and CLL may produce small amounts of M-protein
- Distinguished by lymphadenopathy, splenomegaly, abnormal lymphocyte counts/morphology, and tissue biopsy
- POEMS syndrome [5]: Polyneuropathy, Organomegaly, Endocrinopathy, M-protein (usually small, λ light chain), Skin changes
- Rare but important; the M-protein is usually small (often would qualify as "MGUS" by level alone), but the clinical syndrome is clearly pathological
- Driven by overproduction of VEGF by the clonal plasma cells
- Transient M-proteins can appear after:
- Viral infections (EBV, CMV, hepatitis)
- Immune reconstitution post-chemotherapy or post-transplant
- Autoimmune conditions
- Usually small (< 1 g/dL) and disappear on repeat testing after weeks to months
- Important to repeat SPEP in 2–3 months to confirm persistence before labelling as MGUS
The following table categorises premalignancy and malignancy by monoclonal gammopathy type: [7]
| Type of Monoclonal Gammopathy | Low-Risk Premalignancy (1–2%/year) | High-Risk Premalignancy (10%/year) | Malignancy |
|---|---|---|---|
| IgG and IgA | Non-IgM MGUS | Smouldering MM (SMM) | MM |
| IgM | IgM MGUS | Smouldering WM (SWM) | WM; IgM myeloma (rare) |
| Light chain | Light chain MGUS | Idiopathic Bence Jones proteinuria | Light chain MM |
When you encounter an M-protein, think through the following systematic checklist to ensure you are not missing a more serious diagnosis:
| Question to Ask | What You're Excluding | How to Answer It |
|---|---|---|
| Is the M-protein ≥ 3 g/dL? | SMM or MM | Quantify on SPEP |
| Are BM plasma cells ≥ 10%? | SMM or MM | Bone marrow biopsy |
| Is there hypercalcaemia? | MM (CRAB - C) | Serum calcium (ionised preferred in paraproteinaemia) |
| Is there renal insufficiency? | MM (CRAB - R), MGRS, cast nephropathy, AL amyloidosis | RFT, urine studies, ± renal biopsy |
| Is there anaemia? | MM (CRAB - A) | CBC |
| Are there lytic bone lesions? | MM (CRAB - B) | Low-dose whole-body CT or skeletal survey |
| Is there nephrotic-range proteinuria? | AL amyloidosis, LCDD | 24h urine protein, UPCR |
| Is there unexplained cardiomyopathy? | Cardiac AL amyloidosis, TTR amyloidosis | Echo, ECG, cardiac MRI, ± endomyocardial biopsy |
| Is there peripheral neuropathy? | AL amyloidosis, POEMS, IgM anti-MAG neuropathy | Nerve conduction studies, anti-MAG antibodies |
| Is there organomegaly / skin changes / endocrinopathy? | POEMS | Clinical examination, VEGF levels |
| Is there lymphadenopathy / abnormal lymphocyte count? | Lymphoma, CLL, WM | CBC, CT, ± lymph node biopsy |
| Is the M-protein IgM? | WM, lymphoma | Isotype on immunofixation |
Common Exam Pitfall
A classic exam trap: a patient has a small M-protein, BM plasma cells < 10%, normal CBC, normal calcium, normal creatinine — but has nephrotic-range proteinuria and renal impairment. Students label this as "MGUS" because the clone is small. This is wrong. The correct diagnosis is either AL amyloidosis, LCDD, or MGRS — all require treatment. MGUS is defined by the absence of organ damage attributable to the clone. If the monoclonal protein is damaging an organ, it is not "undetermined significance" — it has determined significance.
An interesting and sometimes-tested laboratory finding:
"Altered anion gap can be seen in paraproteinemia — reduced in IgG gammopathy, increased in IgA gammopathy" [13]
Why? The anion gap = Na⁺ − (Cl⁻ + HCO₃⁻). Immunoglobulins are cationic at physiological pH (they carry positive charge). When IgG (the most positively charged Ig at pH 7.4) is present in excess, it acts as an unmeasured cation → the anion gap formula shows a reduced anion gap. IgA is less positively charged and may behave as an unmeasured anion in some assays → increased anion gap. This is a clue on routine bloods that paraproteinaemia may be present.
High Yield Summary — Differential Diagnosis of MGUS
- MGUS is a diagnosis of exclusion — you must systematically rule out MM, SMM, AL amyloidosis, WM, LCDD, POEMS, lymphoma/CLL, and MGRS before labelling a monoclonal gammopathy as "undetermined significance."
- AL amyloidosis is the most important DDx if the patient has suggestive symptoms [1] — even with a small clone, light chains can cause fatal organ damage.
- The distinction between MGUS, SMM, and MM is based on three parameters: M-protein level, BM plasma cell percentage, and presence of CRAB/MDE.
- IgM MGUS is a distinct entity — the differential includes WM, NHL, and CLL (lymphoproliferative rather than plasma cell lineage).
- The monoclonal gammopathy DDx table by isotype [7]: Non-IgM MGUS → SMM → MM; IgM MGUS → Smouldering WM → WM; LC-MGUS → Idiopathic Bence Jones proteinuria → LC-MM.
- If a small clone causes organ damage (renal, cardiac, neurological), it is not MGUS — consider MGRS, AL amyloidosis, or LCDD.
- An altered anion gap (reduced in IgG, increased in IgA gammopathy) can be a laboratory clue to underlying paraproteinaemia.
Active Recall - Differential Diagnosis of MGUS
References
[1] Lecture slides: GC 030. An old man with bone pain and anaemia.pdf (MGUS slide) [2] Senior notes: Ryan Ho Haemtology.pdf (Section 3.6.2 Monoclonal Gammopathy of Undetermined Significance) [3] Senior notes: Block A - An old man with bone pain and anaemia_ multiple myeloma; monoclonal gammopathy.pdf (Development of myeloma / MGUS section) [4] Senior notes: Block A - Chronic Kidney Disease and its Complications.pdf (Causes of CKD) [5] Senior notes: Maksim Medicine Notes.pdf (Spectrum of plasma cell dyscrasias) [7] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (Differential diagnosis — Spectrum of diseases for monoclonal gammopathy) [8] Lecture slides: Haematology Introduction to Haematological investigations (CBP, Clotting).pdf (Case 1) [9] Senior notes: Block A - Inherited Cardiac conditions.pdf (Amyloidosis workup in DCM) [10] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (Serum and urine immunofixation for amyloidosis/LCDD) [11] Senior notes: Block A – Nephrology Data Interpretation.pdf (Light and heavy chain deposition disease as DDx) [12] Senior notes: Block A - Nephrotology Teaching Clinic RTD.pdf (Renal diseases associated with monoclonal light chains) [13] Senior notes: Block A - Electrolyte and Acid-Base Disorders.pdf (Altered anion gap in paraproteinaemia)
Diagnostic Criteria, Algorithm, and Investigations for MGUS
MGUS is defined by the International Myeloma Working Group (IMWG) criteria. All four criteria must be met simultaneously. Think of it as a four-lock safe — every lock must click shut before you can confidently label something as MGUS.
"Presence of paraprotein of less than 30g/L AND bone marrow plasma cells of less than 10% without any evidence of B cell lymphoproliferative disorder AND absence of organ damage" [1]
| Criterion | Threshold | Why This Threshold? |
|---|---|---|
| 1. Serum M-protein | < 3 g/dL (< 30 g/L) | Higher levels correlate with larger clonal burden → more likely SMM/MM. The 3 g/dL cut-off was derived from population studies showing exponentially ↑ progression risk above this level. |
| 2. Bone marrow clonal plasma cells | < 10% | ≥ 10% indicates SMM or MM. Even a small percentage confirms clonality exists, but < 10% is consistent with a clinically indolent clone. |
| 3. No evidence of B-cell lymphoproliferative disorder | Exclude lymphoma, CLL, WM | Because a small M-protein can be the "tip of the iceberg" of an underlying lymphoid malignancy producing the monoclonal Ig. |
| 4. Absence of end-organ damage | No CRAB features, no MDE | This is the critical dividing line between MGUS and active MM. End-organ damage = the clone is causing harm = treatment is needed. |
High Yield — GC Lecture Slide
The GC 030 slide explicitly states the definition as a single compound statement. In exams, you will likely be asked to recall all four criteria. A common mistake is forgetting "without any evidence of B cell lymphoproliferative disorder" [1] — students often list only three criteria (M-protein, BM %, organ damage) and miss the lymphoproliferative exclusion.
The diagnostic criteria of MGUS vs SMM vs active MM: [5][3][14]
| Feature | MGUS | Smouldering MM | Active MM |
|---|---|---|---|
| Serum M-protein | < 3 g/dL (< 30 g/L) [1] | ≥ 3 g/dL and/or | Any level |
| BM plasma cells | < 10% [1] | 10–60% | ≥ 10% (or biopsy-proven plasmacytoma) [14] |
| End-organ damage (CRAB) | Absent [1] | Absent | Present |
| Myeloma-defining events (SLiM) | Absent | Absent | Present (if any one is met, = active MM even without CRAB) |
| Treatment | Monitoring only [2] | Monitoring (high-risk may enter trials) | Chemotherapy indicated [5] |
| Progression risk | 1%/year [3] | 10%/year (first 5 years) [3] | Already progressed |
These are the criteria that exclude MGUS (i.e., if any of these are present and attributable to the plasma cell clone, the patient has active MM, not MGUS):
End-organ damage: CRAB [5]
| Letter | Feature | Threshold | Pathophysiology |
|---|---|---|---|
| C | Calcium | Adjusted Ca > 2.75 mmol/L (or > 0.25 above ULN) | Osteoclast activation by myeloma cells → bone resorption → Ca²⁺ release |
| R | Renal insufficiency | Creatinine > 177 μmol/L or CrCl < 40 mL/min | Cast nephropathy (FLC obstruct tubules), hypercalcaemia, amyloid |
| A | Anaemia | Hb < 100 g/L (or > 20 g/L below LLN) | BM infiltration by plasma cells crowding out erythropoiesis |
| B | Bone disease | Osteolytic "punched-out" lesions on CT/PET-CT/whole-body MRI | RANKL/DKK1/MIP-1α from myeloma cells activate osteoclasts; ALP usually normal because osteoblastic activity is normal [5] |
Biomarkers of malignancy: SLiM [5]
| Letter | Feature | Threshold | Rationale |
|---|---|---|---|
| S | Sixty | Clonal BM plasma cells ≥ 60% | Ultra-high tumour burden → virtually certain progression |
| Li | Light chain ratio | Involved/uninvolved serum FLC ratio > 100 | Very skewed ratio indicates aggressive monoclonal light chain production |
| M | MRI focal lesions | > 1 focal lesion on MRI (each ≥ 5 mm) | Radiological evidence of marrow involvement even without lytic destruction |
Why SLiM Matters
Before 2014, patients needed overt CRAB damage before they could be diagnosed with active MM. The IMWG added SLiM criteria because studies showed that patients meeting any one of these biomarker thresholds had an ~80% risk of progressing to CRAB damage within 2 years if left untreated. So SLiM = "ultra-high-risk SMM" that is effectively relabelled as active MM to mandate early treatment.
The diagnostic workup for MGUS follows a stepwise approach: first detect the M-protein, then characterise it, then systematically exclude more advanced disease.
3. Investigation Modalities — Detailed Interpretation
What it is: Serum proteins are separated by electrical charge on a gel/capillary. Normally, the gamma-globulin region shows a broad, polyclonal band (many different Ig from many different clones). A monoclonal protein appears as a sharp, narrow spike (M-spike) within or near the gamma region.
"SPE: quantification of M protein" [5]
How to interpret the four patterns of SPE: [15]
| Pattern | Description | What It Suggests |
|---|---|---|
| Normal Ig pattern, absence of paraprotein | Single albumin peak; low flat gamma band | Normal (but could also be non-secretory myeloma — rare) |
| Pan-immunoparesis | All bands low/flat, no peaks | Inherited or acquired immunodeficiencies; light chain myeloma; IgD myeloma; non-secretory myeloma |
| Raised immunoglobulin, absence of paraprotein | Broad elevated gamma band (polyclonal) | Polyclonal hypergammaglobulinaemia — reactive process (chronic infection, autoimmune, liver cirrhosis). Not a plasma cell problem → DO NOT refer to haematology |
| Presence of paraprotein ± immunoparesis | Sharp M-spike ± suppression of background Ig | Monoclonal gammopathy — requires further workup |
In MGUS, the pattern is typically: small M-spike (< 3 g/dL) ± mild immunoparesis of uninvolved immunoglobulins
Common Exam Point
"Raised immunoglobulin, absence of paraprotein on SPE → polyclonal hypergammaglobulinaemia → reactive process → DO NOT refer to haematology" [15]. Students sometimes confuse a polyclonal elevation with a monoclonal spike. The key visual clue: polyclonal = broad dome; monoclonal = sharp spike.
What it is: After electrophoresis, specific antisera are overlaid against each heavy chain (IgG, IgA, IgM) and each light chain (κ, λ). The antiserum that "fixes" (precipitates) the M-band tells you exactly what type of monoclonal protein is present.
"Immunofixation: characterize type of M protein, e.g. IgGκ (most common)" [5]
Why it matters for MGUS:
- Determines the isotype — this feeds into risk stratification (non-IgG type = higher risk of progression)
- IgM isotype shifts the differential toward WM/lymphoma rather than MM
- "Both SPE and UPE at diagnosis is mandatory: 50% of light chain MM is SPE-negative but UPE-positive" [5] — this isn't directly about MGUS, but it reminds you to always do urine studies to catch light-chain-only disease
What it is: A quantitative assay measuring unbound (free) κ and λ light chains in serum, plus their ratio.
- Normal κ:λ ratio: 0.26–1.65 [5]
- An abnormal ratio indicates monoclonal excess of one light chain type
- "Serum FLC: more sensitive for monoclonal FLC, κ:λ ratio also suggests monoclonal origin" [5]
Why it matters for MGUS:
- Diagnosis of LC-MGUS: some patients have no intact M-protein on SPEP but an abnormal FLC ratio — this is light-chain MGUS
- Risk stratification: an abnormal FLC ratio is one of the three factors in the Mayo Clinic risk model
- Progression to MM: a ratio > 100 is a myeloma-defining event (SLiM criteria) [5]
- "Light chain ratio approaching 100 = poor prognostic marker" [3]
- Urine protein electrophoresis (UPE) with immunofixation: detects monoclonal free light chains (Bence Jones protein) in urine
- "24h urine: Bence Jones protein (FLC)" [5]
- In MGUS, Bence Jones protein may be absent or present in small quantities (< 500 mg/24h by convention)
- Heavy proteinuria (> 1 g/day of monoclonal light chains) should raise concern for SMM, MM, AL amyloidosis, or cast nephropathy
Why "Bence Jones"? Named after Henry Bence Jones (1848) who described urine proteins that precipitate when heated to 56°C and redissolve at 100°C. These are monoclonal free light chains that are small enough to pass through the glomerular filter.
In MGUS, CBC/PBS are usually normal ± rouleaux formation [2]
| Finding | Interpretation | Pathophysiology |
|---|---|---|
| Normal Hb | Expected in MGUS (no marrow failure) | Clone too small to crowd out erythropoiesis |
| Rouleaux formation | Non-specific; indicates ↑ protein level [2] | M-protein bridges RBC surfaces → stacking like coins; causes falsely ↑ ESR |
| Anaemia | If present → consider MM, AL amyloidosis, or other cause | BM infiltration, EPO deficiency from renal impairment, or haemodilution |
| Circulating plasma cells | > 2 × 10⁹/L or > 20% WCC → plasma cell leukaemia [16] | Fulminant disease; excludes MGUS |
| Test | Expected in MGUS | Abnormal Values and What They Suggest |
|---|---|---|
| Calcium | Normal | ↑ Ca → MM (osteolysis) or factitious (paraprotein binding); always check ionised Ca in paraproteinaemia [6] |
| Creatinine/eGFR | Normal | ↑ Cr → cast nephropathy, MGRS, amyloidosis, hypercalcaemia |
| Albumin | Normal or mildly ↓ | ↓ Albumin → advanced disease (prognostic in ISS staging), AL amyloidosis |
| LDH | Normal | ↑ LDH → aggressive disease, R-ISS staging |
| β2-microglobulin | Normal or mildly ↑ with age | Important for prognosis; must be checked at diagnosis as levels change after treatment [16]; ↑ in renal impairment or high tumour burden |
| Quantitative Ig (IgG, IgA, IgM) | Usually normal or mild immunoparesis | Immunoparesis = suppression of uninvolved Ig classes → ↑ infection risk; more pronounced = more concerning |
| Total protein + A:G ratio | Reversed A:G ratio with ↑ globulin [2] | Albumin remains normal but globulin rises due to M-protein → A:G inverts |
| ESR | Elevated (often markedly) [2] | Rouleaux → ↑ sedimentation; can be > 100 mm/hr with even modest M-proteins |
Chemical Pathology Pearl — Factitious Hypercalcaemia
"Paraproteinaemia, e.g. MGUS — significantly ↑ total protein with normal albumin → ↑ globulin; apparent high Ca → due to high globulin; Ig may precipitate with PO₄, interfering with measurement" [6]. In the exam, if you see ↑ total calcium + ↑ globulin + normal albumin in an elderly patient, think: Is this real hypercalcaemia or a paraprotein artifact? Check ionised calcium.
This is the definitive investigation for confirming MGUS (and excluding MM/SMM).
"BM: by definition < 10% clonal plasma or lymphoplasmacytic cells" [2]
| Component | What It Shows | Why It's Needed |
|---|---|---|
| Aspirate (smear) | Permits cytology, flow cytometry, and genetic studies [17] | Count plasma cell %, assess morphology |
| Trephine biopsy | Permits histological examination (marrow cellularity, architectural details, fibrosis, bone structure) and immunohistochemistry [17] | Detect patchy involvement (aspirate may falsely underestimate); IHC for CD138, κ/λ restriction |
| Morphology | Generally round, eccentric 'clock-face' nucleus with marked perinuclear cytoplasmic clearing [16] | Typical plasma cell morphology; atypical/immature morphology suggests more aggressive disease |
| Immunophenotyping | CD138, κ/λ light chain expression [16] | Confirms clonality (light chain restriction = all cells express same LC type) |
| Cytogenetics/FISH | Detect IgH translocations, hyperdiploidy, del(17p), 1q gain | Risk stratification; high-risk cytogenetics [t(4;14), del(17p)] suggest closer monitoring even in "MGUS" |
"Bone marrow morphology" is listed as one of the five risk factors for progression on the GC lecture slide [1]. "Ugly looking plasma cells, clinical course worse" [3].
Is BM Biopsy Always Needed in Suspected MGUS?
Technically, the IMWG definition requires BM confirmation of < 10% clonal plasma cells. However, in clinical practice, some guidelines allow deferral of BM biopsy in low-risk patients (IgG type, M-protein < 1.5 g/dL, normal FLC ratio, no symptoms). The decision is individualised. In an exam setting, always mention BM biopsy as part of the diagnostic workup.
The purpose is to exclude lytic bone lesions (CRAB — B criterion), which would upgrade the diagnosis from MGUS to active MM.
"Skeletal survey – hypermetabolic lesions with PET/CT and bone scintigraphy" [11]
| Modality | Details | Findings in MGUS vs MM |
|---|---|---|
| Skeletal survey (conventional X-ray) | PA chest, AP/lateral C/T/L-spine, AP/lateral femur/humerus, AP/lateral skull, AP pelvis [16] | MGUS: normal. MM: punched-out lytic lesions (60%), diffuse osteopenia, pathological fractures (20%) [16] |
| Whole-body low-dose CT | Now preferred due to ↑ sensitivity [16] | More sensitive than plain X-ray for small lytic lesions |
| Whole-body MRI | Excellent soft-tissue contrast; detects marrow infiltration | > 1 focal lesion ≥ 5 mm = myeloma-defining event (SLiM — M) |
| PET/CT | Detects hypermetabolic lesions | Usually preferred in QMH [16]; functional + anatomical |
Why is ALP usually normal in myeloma? Because myeloma activates osteoclasts (bone breakdown) but does not activate osteoblasts (bone formation). ALP is produced by osteoblasts, so it stays normal. This distinguishes myeloma lytic lesions from metastatic carcinoma (which often has ↑ ALP due to mixed lytic-blastic response). [5]
If there is any clinical suspicion of organ deposition:
| Investigation | Purpose |
|---|---|
| Abdominal fat pad aspirate | Least invasive screening biopsy for amyloid; Congo red stain → apple-green birefringence under polarised light |
| Tissue biopsy (renal, endomyocardial, rectal) | Direct demonstration of amyloid deposits in affected organ |
| Congo red stain → salmon pink colour | Indicative of amyloid deposition [18] |
| Electron microscopy | Non-branching fibrils in the extracellular compartment [18] |
| NT-proBNP, Troponin | Cardiac biomarkers for subclinical cardiac amyloid involvement |
| Echocardiography + ECG | Small QRS voltages + thickened LV wall = classical for amyloidosis [9] |
| 99mTc-PYP scan | For transthyretin (TTR) amyloidosis [9] — important to distinguish AL from ATTR |
These are not for MGUS itself (which requires no treatment) but are important to know as part of the myeloma workup if the patient progresses:
"Pre-Tx: HBsAg, anti-HBc ± HBV DNA, G6PD" [5] — because:
- HBV screening: immunomodulatory therapy (e.g., lenalidomide) and steroids can cause HBV reactivation → must screen before starting
- G6PD: some chemotherapy agents can cause haemolysis in G6PD-deficient patients
4. Risk Stratification of Confirmed MGUS
Once MGUS is confirmed, the next step is risk stratification to determine follow-up intensity.
Uses three factors:
| Factor | Threshold |
|---|---|
| 1. M-protein level | ≥ 1.5 g/dL |
| 2. Isotype | Non-IgG (i.e., IgA, IgM) |
| 3. Serum FLC ratio | Abnormal (< 0.26 or > 1.65) |
| Risk Group | Number of Risk Factors | Absolute Risk of Progression at 20 Years |
|---|---|---|
| Low | 0 | ~5% |
| Low-intermediate | 1 | ~21% |
| High-intermediate | 2 | ~37% |
| High | 3 | ~58% |
Risk of progression to myeloma depends on: Size of paraprotein, Type of paraprotein, Light chain ratio, Rate of rise in paraprotein, Bone marrow morphology [1]
| Risk Category | Recommended Follow-Up |
|---|---|
| Low risk (0 factors) | Repeat SPEP, sFLC, CBC, Ca, creatinine at 6 months, then if stable, every 2–3 years or when symptoms develop |
| Intermediate/High risk (1–3 factors) | Repeat at 6 months, then annually with SPEP, sFLC, CBC, Ca, creatinine |
| Any category — new symptoms | Immediate reassessment with full workup (BM biopsy, imaging) |
The key variables to monitor at each visit:
- M-protein level (is it rising? — "Rate of rise in paraprotein — rapid rise is alarming, require monitoring soon" [3])
- sFLC ratio (is it becoming more abnormal?)
- CBC (new anaemia?)
- Calcium (new hypercalcaemia?)
- Creatinine (new renal impairment?)
- Symptoms: new bone pain, fatigue, weight loss, recurrent infections
| Investigation | Key Finding in MGUS | What an Abnormality Means |
|---|---|---|
| SPEP | M-spike < 3 g/dL | > 3 g/dL → SMM/MM |
| Immunofixation | Identifies isotype (IgG κ most common) | IgM → think WM; Non-IgG → ↑ risk |
| sFLC + ratio | May be normal or mildly abnormal (ratio 0.26–1.65) | Ratio > 100 → MDE (active MM) |
| 24h urine + UPE | Absent or minimal Bence Jones protein | Heavy BJP → SMM/MM/AL amyloidosis |
| CBC/PBS | Normal ± rouleaux | Anaemia → MM; Circulating plasma cells → PCL |
| Calcium (ionised) | Normal | ↑ → MM (or factitious if total Ca only) |
| RFT | Normal | ↑ Cr → cast nephropathy/MGRS/amyloid |
| Quantitative Ig | Normal or mild immunoparesis | Severe immunoparesis → closer monitoring |
| β2-microglobulin | Normal or age-related mild ↑ | ↑ → staging (ISS) for MM |
| BM biopsy | < 10% clonal plasma cells | ≥ 10% → SMM/MM |
| Skeletal imaging | Normal | Lytic lesions → MM |
| Tissue biopsy (if indicated) | No amyloid | Congo red +ve → AL amyloidosis |
High Yield Summary — Diagnostic Criteria, Algorithm, and Investigations
- MGUS diagnostic criteria (all must be met): M-protein < 3 g/dL; BM plasma cells < 10%; no B-cell lymphoproliferative disorder; no end-organ damage (CRAB/SLiM) [1]
- CRAB = Calcium ↑, Renal insufficiency, Anaemia, Bone lesions. SLiM = Sixty % BM PC, Light chain ratio > 100, MRI > 1 focal lesion. Any CRAB or SLiM = active MM, not MGUS [5]
- Investigation trio for monoclonal gammopathy screening: SPEP with immunofixation + serum FLC + 24h urine for BJP [5]
- SPEP patterns: Normal / Pan-immunoparesis / Polyclonal ↑ (reactive, do NOT refer to haematology) / M-spike ± immunoparesis [15]
- Normal κ:λ ratio = 0.26–1.65; abnormal suggests monoclonal origin [5]
- BM biopsy is definitive: confirms < 10% clonal PC, provides morphology, immunophenotyping (CD138, light chain restriction), and cytogenetics for risk stratification
- Skeletal imaging (WB low-dose CT preferred) must be normal in MGUS; ALP is usually normal in myeloma because osteoblastic activity is preserved [5]
- Risk stratification: Mayo Clinic model uses M-protein ≥ 1.5, non-IgG isotype, abnormal FLC ratio → 0–3 risk factors determining surveillance intensity
- Always exclude AL amyloidosis if any suggestive symptoms — even a small clone can produce lethal amyloid deposits [1]
- Factitious hypercalcaemia: paraprotein binds calcium → ↑ total Ca with normal ionised Ca; check ionised Ca [6]
Active Recall - Diagnostic Criteria, Algorithm, and Investigations for MGUS
References
[1] Lecture slides: GC 030. An old man with bone pain and anaemia.pdf (MGUS slide) [2] Senior notes: Ryan Ho Haemtology.pdf (Section 3.6.2 Monoclonal Gammopathy of Undetermined Significance) [3] Senior notes: Block A - An old man with bone pain and anaemia_ multiple myeloma; monoclonal gammopathy.pdf (Development of myeloma / MGUS section) [5] Senior notes: Maksim Medicine Notes.pdf (Multiple myeloma investigations, diagnostic criteria, SLiM CRAB) [6] Senior notes: Ryan Ho Chemical Path.pdf (Paraproteinaemia and factitious hypercalcaemia) [8] Lecture slides: Haematology Introduction to Haematological investigations (CBP, Clotting).pdf (Case 1) [9] Senior notes: Block A - Inherited Cardiac conditions.pdf (Amyloidosis workup in DCM) [11] Senior notes: Block A – Nephrology Data Interpretation.pdf (Skeletal survey, monoclonal gammopathy workup) [14] Senior notes: Block A - An old man with bone pain and anaemia_ multiple myeloma; monoclonal gammopathy.pdf (MGUS vs SMM vs MM comparison table) [15] Senior notes: Block A - Introduction to Haematological investigations (CBP, Clotting).pdf (Interpretation of SPE — 4 patterns) [16] Senior notes: Ryan Ho Haemtology.pdf (MM laboratory findings, skeletal imaging, ISS staging) [17] Senior notes: Ryan Ho Fundamentals.pdf (Bone marrow examination — aspirate vs trephine) [18] Senior notes: Block A - Hematology Data Interpretation.pdf (Congo red stain, electron microscopy for amyloidosis)
Management of MGUS
Before diving into the algorithm, the single most important concept must be crystal clear:
"Only multiple myeloma patients will be symptomatic with organ involvement → requires treatment. Other forms do not require treatment → require monitoring." [3]
MGUS management is monitoring only [2]. There is no chemotherapy, no immunotherapy, no radiation for MGUS itself. This is not a disease that requires treatment — it is a risk state that requires surveillance. The entire management strategy is about two things:
- Confirming the diagnosis is truly MGUS (not something masquerading as MGUS)
- Detecting progression early before irreversible organ damage occurs
Why no treatment? Because:
- The clone is too small to cause harm
- Available therapies carry toxicity (immunosuppression, neuropathy, secondary malignancies)
- The annual progression risk is only ~1% — treating all MGUS patients would mean subjecting ~99 people per year to toxic therapy unnecessarily for every 1 who would progress
- Some patients can convert from MGUS back to normal [3] — the clone can spontaneously regress
3. Detailed Management Components
Risk of progression to myeloma depends on: Size of paraprotein, Type of paraprotein, Light chain ratio, Rate of rise in paraprotein, Bone marrow morphology [1]
The Mayo Clinic model is the most widely used clinical tool:
| Risk Factors Present | Risk Group | 20-year Progression | Suggested Follow-up |
|---|---|---|---|
| 0 of 3 | Low | ~5% | 6 months → every 2–3 years |
| 1 of 3 | Low-intermediate | ~21% | 6 months → annually |
| 2 of 3 | High-intermediate | ~37% | 6 months → every 6–12 months |
| 3 of 3 | High | ~58% | 6 months → every 6–12 months |
The Spanish PETHEMA model adds BM immunophenotyping (aberrant vs normal plasma cell phenotype) and DNA aneuploidy as additional discriminators, but the Mayo model is more commonly referenced in HK exams.
At each surveillance visit, the following should be assessed:
| Test | What You're Looking For | Rationale |
|---|---|---|
| SPEP with immunofixation | Rising M-protein level; appearance of new M-protein | "Rate of rise in paraprotein — rapid rise is alarming, require monitoring soon" [3]. A rise of ≥ 0.5 g/dL/year or M-protein crossing 3 g/dL suggests transition to SMM. |
| Serum free light chains + κ:λ ratio | Increasingly abnormal ratio; ratio approaching or exceeding 100 | "Light chain ratio approaching 100 = poor prognostic marker" [3]. A ratio > 100 = myeloma-defining event → immediate action |
| CBC | New anaemia (Hb < 100), new cytopenias | Anaemia = CRAB criterion (A). New thrombocytopenia or leukopenia suggests marrow infiltration |
| Serum calcium (ionised preferred) | New hypercalcaemia | CRAB criterion (C). Remember to always check ionised Ca to avoid being misled by factitious hypercalcaemia from paraprotein binding [6] |
| Serum creatinine / eGFR | New renal impairment | CRAB criterion (R). Decline in eGFR may indicate cast nephropathy, amyloidosis, or LCDD |
| Clinical assessment | New bone pain, fatigue, weight loss, recurrent infections, neuropathy, features of amyloidosis | Any new symptom warrants expedited full workup |
When to Urgently Re-Evaluate
The patient should be educated to return immediately (not wait for scheduled follow-up) if they develop:
- New bone pain (especially back, ribs, pelvis)
- Unexplained fatigue or pallor
- Recurrent or severe infections
- Excessive thirst/polyuria (hypercalcaemia)
- Foamy urine (proteinuria)
- Numbness/tingling in hands/feet (neuropathy → amyloidosis or POEMS)
- Swelling of ankles (nephrotic syndrome → amyloidosis)
BM biopsy is not repeated routinely in stable MGUS. It is indicated when:
- M-protein rises significantly (e.g., ≥ 25% increase from baseline, or crosses 3 g/dL)
- sFLC ratio becomes markedly abnormal
- New CRAB features develop
- Clinical suspicion of transformation (new symptoms, new cytopenias)
3.4 Addressing Associated Risks in MGUS Patients
Although MGUS doesn't require anti-neoplastic treatment, these patients face real health risks that warrant proactive management:
MGUS patients have a 2–3× increased risk of osteoporotic fracture compared to age-matched controls, even without lytic lesions. The mechanisms include:
- Low-level osteoclast activation by clonal plasma cell-derived cytokines (RANKL, DKK1)
- Immunoparesis → chronic inflammation → bone loss
- Older age (the population most affected by MGUS is already at risk)
Management:
- DXA scan for baseline BMD assessment
- Vitamin D and calcium supplementation as appropriate
- Bisphosphonates are NOT routinely given for MGUS alone (unlike active MM), but may be indicated if the patient has coexisting osteoporosis by standard criteria
MGUS patients have immunoparesis — suppression of uninvolved (normal, polyclonal) immunoglobulins. This translates to a real, measurable increase in infection risk, particularly for encapsulated organisms.
Management:
- Annual influenza vaccination
- Pneumococcal vaccination (PCV20 or PCV15 + PPSV23 sequential strategy)
- COVID-19 vaccination (MGUS patients may have suboptimal antibody responses)
- Low threshold for investigating febrile illness — counsel patient and GP
MGUS is associated with a ~2× increased risk of VTE. The mechanism is likely multifactorial:
- Paraprotein-mediated activation of coagulation pathways
- Acquired activated protein C resistance
- Possible anti-phospholipid antibody-like activity of the M-protein
Management:
- No routine anticoagulation (the risk is too small to justify)
- Patient education on VTE symptoms (leg swelling, sudden breathlessness)
- Attention to VTE prophylaxis during hospitalisation or surgery
Even in "true" MGUS, there is a small risk of the monoclonal protein causing subclinical renal damage (the spectrum of MGRS — Monoclonal Gammopathy of Renal Significance). Routine monitoring of creatinine and urinalysis helps catch this early.
If proteinuria develops → check urine protein quantification and refer for nephrology evaluation ± renal biopsy.
4. What Happens If MGUS Progresses?
Although this section focuses on MGUS management (which is surveillance), it is important to understand the framework of what follows if progression occurs, as this is commonly tested.
- M-protein rises ≥ 3 g/dL and/or BM plasma cells reach 10–60%
- Still no CRAB/SLiM
- Management: closer monitoring (every 3–6 months); some centres enrol high-risk SMM patients in clinical trials of early intervention (e.g., lenalidomide-based regimens), but standard of care remains observation outside trials
When any CRAB or SLiM criterion is met, the patient is reclassified as active MM and specific chemotherapy is indicated [5]:
"Specific chemotherapy: only indicated in active MM" [5]
The MM treatment framework (for context — not treatment of MGUS itself):
| Phase | Regimen | Key Agents |
|---|---|---|
| Induction | Triple therapy [5] | Proteasome inhibitor (e.g., bortezomib, carfilzomib) + Immunomodulatory agent (e.g., lenalidomide, thalidomide, pomalidomide) + Dexamethasone |
| Transplant assessment | Determine eligibility | Age < 60, no significant comorbidities [5] |
| Transplant eligible | 4 cycles triple therapy → high-dose melphalan + autologous HSCT [5] | Melphalan = alkylating agent that ablates BM |
| Transplant ineligible | 8–12 cycles of triple therapy [5] | Extended induction without transplant |
| Consolidation + Maintenance | Lenalidomide monotherapy ≥ 2 years [5] | Maintains response, delays relapse |
| Relapsed/Refractory | Anti-CD38 (daratumumab, isatuximab), SLAMF7 (elotuzumab) [5] | Monoclonal antibodies targeting myeloma cells |
| Immunotherapy against BCMA | ADC, BiTE, CAR-T [5] | Newest modalities for multiply-relapsed disease |
Supportive treatment for active MM: [5]
- TLS prophylaxis: IV fluid + allopurinol/febuxostat
- Hypercalcaemia/Bone disease: local RT for pain, aggressive hydration > 3L/day, bisphosphonates (e.g., pamidronate), denosumab (RANKL inhibitor)
- Renal failure: hydration, avoid nephrotoxins (e.g., NSAID), dialysis PRN
Why These Agents Are NOT Used in MGUS
Let's briefly understand why each class of MM drug would be inappropriate for MGUS:
-
Proteasome inhibitors (bortezomib): "Inhibition of 26S proteasome → prevent proteolysis of ubiquitin-tagged protein → cytotoxic to myeloma cells by affecting multiple signalling cascades" [14]. Side effects include peripheral neuropathy, thrombocytopenia, and herpes zoster reactivation. Giving this to a patient with a benign, asymptomatic condition would cause harm without benefit.
-
Immunomodulatory agents (lenalidomide, thalidomide): Teratogenic, cause cytopenias, increase VTE risk. The risk-benefit ratio is only favourable when the alternative is death or organ destruction from myeloma.
-
Dexamethasone: Chronic high-dose steroids cause cushingoid features, diabetes, osteoporosis, immunosuppression. Justified only when controlling aggressive disease.
-
HSCT: Carries 1–2% treatment-related mortality. Only justified when the disease itself threatens life.
The principle: primum non nocere (first, do no harm). MGUS patients live with their condition for years to decades. Exposing them to toxic therapy for a 1%/year progression risk would cause far more harm than good.
"AL amyloidosis is a DDx if patient has suggestive symptoms" [1]
If an MGUS patient develops features of AL amyloidosis (cardiac failure, nephrotic syndrome, neuropathy, macroglossia), tissue biopsy confirmation is needed, followed by clone-directed therapy:
- Similar agents to myeloma (bortezomib-based regimens, ± daratumumab)
- Goal: eradicate or suppress the clone to halt light chain production and amyloid deposition
- Supportive: diuretics for fluid overload, pacemaker for conduction disease, ACEi contraindicated (can cause profound hypotension in cardiac amyloid)
If IgM MGUS progresses to symptomatic WM (hyperviscosity, cytopenias, lymphadenopathy):
- Treatment: rituximab-based regimens (rituximab + bendamustine, or rituximab + ibrutinib)
- Plasmapheresis for acute hyperviscosity syndrome
5. Special Situations in MGUS Management
- Important to document MGUS in surgical pre-assessment
- Elevated ESR and abnormal globulins should not delay surgery (they are expected findings)
- Ensure VTE prophylaxis is adequate (MGUS ↑ VTE risk)
- Avoid nephrotoxic agents peri-operatively (NSAIDs, contrast dye — always hydrate well)
- IV iodinated contrast is generally safe in MGUS with normal renal function
- In patients with Bence Jones proteinuria or borderline renal function → ensure aggressive pre- and post-hydration to prevent contrast-induced nephropathy and cast nephropathy exacerbation
- Bisphosphonates are NOT routinely indicated for MGUS (unlike active MM where they are standard)
- However, if the patient has coexisting osteoporosis (T-score ≤ −2.5 on DXA), bisphosphonates are given for osteoporosis per standard guidelines
- "IV bisphosphonates cannot be used in patients with eGFR less than 35 mL/min → denosumab not excreted through kidneys, can be given to these CKD patients" [19] — relevant if the MGUS patient has coexisting CKD
- IgM MGUS-associated anti-MAG neuropathy may warrant treatment even though the "MGUS" clone itself is small
- Options: rituximab (targets the IgM-producing clone), IVIG, plasma exchange
- This is technically treating the consequences of the monoclonal protein, not treating MGUS as a malignancy
- As discussed in previous sections, MGRS is MGUS-level clone burden but with direct renal pathology
- Treatment of the clone IS indicated in MGRS — because the kidney damage will progress without intervention
- Regimens are clone-directed, similar to myeloma induction (bortezomib-based), tailored to the specific renal lesion
An often-overlooked but critically important aspect of MGUS management. Telling a patient they have a "pre-cancer" condition requires careful communication:
| Key Message | How to Frame It |
|---|---|
| "You have an abnormal protein in your blood" | Explain simply: one of your immune cells is making too much of one type of protein |
| "It is NOT cancer" | Currently no damage to your body; it's a risk state, like having high cholesterol is a risk for heart disease |
| "It needs monitoring, not treatment" | We follow it with regular blood tests, like we monitor blood pressure |
| "The risk of it progressing is small" | ~1% per year; the vast majority of people with MGUS never develop a problem |
| "Come back if you have new symptoms" | Bone pain, unusual fatigue, recurrent infections, swelling → tell us immediately |
| Component | Action | Rationale |
|---|---|---|
| Anti-neoplastic therapy | NOT indicated | Risk-benefit ratio unfavourable; clone is benign by definition |
| Risk stratification | Mayo Clinic model (3 factors) | Determines surveillance intensity |
| Surveillance bloods | SPEP, sFLC, CBC, Ca, Cr | Detect rising M-protein, new CRAB criteria |
| Surveillance schedule | 6 months → then yearly or 2–3 yearly depending on risk | Balance between early detection and over-medicalisation |
| BM re-biopsy | Only if progression suspected | Not routine in stable MGUS |
| Bone health | DXA, Vit D, Ca supplementation ± bisphosphonates for osteoporosis | MGUS ↑ fracture risk independent of lytic lesions |
| Infection prevention | Vaccinations (influenza, pneumococcal, COVID) | Immunoparesis → ↑ infection risk |
| VTE awareness | Patient education; peri-operative prophylaxis | ~2× ↑ VTE risk |
| Patient education | Explain condition, reassure, outline red flags | Reduce anxiety; ensure early presentation if symptoms develop |
High Yield Summary — MGUS Management
- "Management: monitoring only" [2] — no chemotherapy, no immunotherapy for MGUS itself.
- "Only multiple myeloma patients will be symptomatic with organ involvement → requires treatment. Other forms do not require treatment → require monitoring." [3]
- Risk stratification uses the Mayo Clinic 3-factor model: M-protein ≥ 1.5 g/dL, non-IgG isotype, abnormal sFLC ratio.
- Surveillance: SPEP, sFLC ratio, CBC, calcium, creatinine — at 6 months, then annually or 2–3 yearly depending on risk group.
- Rate of rise in paraprotein is a key monitoring parameter [1][3] — a rapid rise warrants expedited workup including BM biopsy and imaging.
- Associated risk management: bone health (DXA, Vit D), infection prevention (vaccinations), VTE awareness.
- Exceptions where clone-directed treatment IS indicated despite MGUS-level tumour burden: MGRS (renal damage from M-protein), AL amyloidosis (organ deposition), and IgM MGUS with symptomatic anti-MAG neuropathy.
- If MGUS progresses to active MM: triple therapy (proteasome inhibitor + IMiD + dexamethasone) ± autologous HSCT [5].
- Bisphosphonates are NOT routinely used in MGUS — only if coexisting osteoporosis. For patients with CKD (eGFR < 35): denosumab instead of IV bisphosphonates [19].
- Patient education is crucial: reassure (not cancer), explain monitoring plan, and teach red-flag symptoms for urgent return.
Active Recall - Management of MGUS
References
[1] Lecture slides: GC 030. An old man with bone pain and anaemia.pdf (MGUS slide) [2] Senior notes: Ryan Ho Haemtology.pdf (Section 3.6.2 Monoclonal Gammopathy of Undetermined Significance) [3] Senior notes: Block A - An old man with bone pain and anaemia_ multiple myeloma; monoclonal gammopathy.pdf (Development of myeloma / MGUS section) [5] Senior notes: Maksim Medicine Notes.pdf (MM management, diagnostic criteria, SLiM CRAB, chemotherapy regimens) [6] Senior notes: Ryan Ho Chemical Path.pdf (Paraproteinaemia and factitious hypercalcaemia) [14] Senior notes: Block A - An old man with bone pain and anaemia_ multiple myeloma; monoclonal gammopathy.pdf (Proteasome inhibitors, novel agents) [19] Senior notes: Block A - Confused and dehydrated_ hypercalcaemia; hypocalcaemia.pdf (Denosumab in renal impairment, bisphosphonate contraindication)
Complications of MGUS
Before listing complications, it is important to understand a key distinction. MGUS is, by definition, a condition without end-organ damage. So when we talk about "complications of MGUS," we are really discussing two categories:
- Complications arising from the monoclonal protein itself — even though the clone is small and does not meet criteria for malignancy, the circulating M-protein (or its free light chains) can still exert biological effects on various organ systems
- The risk of malignant transformation — MGUS is a premalignant state, and progression to a frank haematological malignancy is the most feared long-term complication
Think of MGUS as a dormant volcano. It is not erupting (no CRAB damage), but the thermal vents (the M-protein) can still cause local effects, and there is always the risk that the volcano wakes up.
1. Malignant Transformation — The Most Important Complication
This is the complication that defines the entire management strategy of MGUS.
"Risk of progression of MGUS to myeloma is 1% per year" [3]
| MGUS Subtype | Annual Progression Risk | What It Can Progress To |
|---|---|---|
| Non-IgM MGUS | 0.8%/year [2] | MM, plasmacytoma, AL amyloidosis [2] |
| IgM MGUS | 2%/year in first 10 years, then ~1%/year [2] | Waldenström macroglobulinaemia, AL amyloidosis, NHL, CLL [2] |
| LC-MGUS | 0.3%/year [2] | Idiopathic Bence Jones proteinuria (LC-SMM), light chain MM [2] |
At 25 years of follow-up, 25–30% of MGUS patients will have progressed [2]. However, because the median age of diagnosis is 65–70 years [2], many patients will die of other causes before progression occurs. This is why overall lifespan is only slightly reduced: 8.1 years vs 12.4 years in matched controls [2].
"MGUS (Asymptomatic) → SMM (Asymptomatic) → MM (Symptomatic) → Extramedullary MM / Plasma cell leukaemia" [7]
Risk factors for progression: [1]
- Size of paraprotein — "Small, lower chance" [3]
- Type of paraprotein — non-IgG types carry higher risk
- Light chain ratio — "Approaching 100, poor prognostic marker" [3]
- Rate of rise in paraprotein — "Rapid rise is alarming, require monitoring soon" [3]
- Bone marrow morphology — "Ugly looking plasma cells, clinical course worse" [3]
High Yield — Past Paper Question (2023 Fourth Summative)
Question 44: "Ms. Chan is recently diagnosed IgG lambda MGUS. Her IgG level was 1900 mg/dL and other immunoglobulin levels were normal. Her paraprotein level was 5 g/L. Her other blood tests were normal. What is her MOST LIKELY prognosis?" [20]
The correct answer is B: She has 1% risk of progression into myeloma after one year of follow-up. Explanation:
- Option A is wrong: the condition may not remain stable — MGUS always carries a progression risk, regardless of immunoparesis status.
- Option B is correct: MGUS carries ~1% per year risk of progression [3].
- Option C (10%/year) describes SMM, not MGUS.
- Option D is wrong: not all IgG lambda MGUS patients develop amyloidosis — AL amyloidosis is a DDx to consider, but it is not inevitable.
This question directly tests whether you know the annual progression rate of MGUS (1%) vs SMM (10%).
Once a patient progresses to active MM, they develop the CRAB complications:
"HyperCalcaemia / Bone lesions: active osteoclasts ... Renal failure ... Anaemia (NcNc) / bleeding tendency: BM infiltration + acquired vWD" [5]
The key point is that these are complications of MM, not of MGUS itself. In MGUS, these features are by definition absent. Their development signals that the patient has left the MGUS state.
2. AL Amyloidosis
"AL amyloidosis is a DDx if patient has suggestive symptoms" [1]
This is arguably the most important "complication" of MGUS, though it is more accurately described as a disease that can arise from or coexist with an MGUS-level clone.
- The clonal plasma cells produce monoclonal free light chains
- Certain light chains (especially λ) have a propensity to misfold into β-pleated sheet structures (amyloid fibrils)
- These fibrils deposit in tissues: heart, kidneys, nerves, liver, GI tract, soft tissues
- The deposits are Congo red positive (apple-green birefringence under polarised light) and consist of non-branching fibrils on electron microscopy [18]
- Crucially, AL amyloidosis can occur with a very small clone — the BM plasma cells may be < 10% and the M-protein < 3 g/dL
| Organ | Manifestation | Mechanism |
|---|---|---|
| Heart | Restrictive cardiomyopathy, HFpEF, arrhythmias, conduction blocks | Amyloid fibrils infiltrate myocardium → stiff, non-compliant walls |
| Kidney | Nephrotic syndrome (heavy proteinuria, oedema) | Amyloid deposits in glomeruli → disruption of filtration barrier |
| Nerves | Peripheral sensorimotor neuropathy, autonomic neuropathy (postural hypotension, early satiety, constipation/diarrhoea) | Amyloid deposits in vasa nervorum and endoneurium |
| Soft tissue | Macroglossia, periorbital purpura, carpal tunnel syndrome | Direct amyloid infiltration of tongue, small vessels, flexor retinaculum |
| Liver | Hepatomegaly, elevated ALP | Sinusoidal and periportal amyloid deposition |
| GI tract | Malabsorption, GI bleeding | Mucosal/submucosal amyloid deposition |
Non-IgM MGUS has an increased risk of AL amyloidosis [2]. The annual rate is included within the overall ~0.8%/year progression figure.
Why AL Amyloidosis Can Be Fatal Even With a Tiny Clone
Students sometimes think: "The clone is small (< 10% BM plasma cells), so it can't be dangerous." This is wrong. In AL amyloidosis, it is not the tumour burden that kills — it is the toxicity of the protein product. Even a small factory producing toxic waste can poison the whole neighbourhood. Untreated cardiac AL amyloidosis has a median survival of ~6 months. This is why the GC slide specifically states: "AL amyloidosis is a DDx if patient has suggestive symptoms" [1].
3. Infections and Immunoparesis
Even in MGUS, the clonal plasma cell population can suppress normal polyclonal immunoglobulin production — a phenomenon called immunoparesis. The mechanism involves:
- Clonal dominance of the BM niche → crowding out normal plasma cell precursors
- Immunoregulatory cytokines produced by the clone (e.g., TGF-β, IL-10) that suppress normal B-cell differentiation
- The result is reduced levels of uninvolved (normal) immunoglobulins (e.g., in IgG MGUS: IgA and IgM may be suppressed)
"Recurrent infections: immunoparesis (↓↓ other Ig)" [5] — this is listed as a complication of MM, but immunoparesis begins even at the MGUS stage, just to a lesser degree.
- MGUS patients have a ~2-fold increased risk of bacterial infections compared to age-matched controls
- Particularly susceptible to encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae) — because opsonisation requires intact antibody responses
- "Due to ↓ opsonization of encapsulated organisms by Ig production" [16]
- Risk is proportional to the degree of immunoparesis — more suppressed uninvolved Ig = higher infection risk
- Pneumococcal and influenza vaccination recommended
- Low threshold for investigating febrile episodes
- Consider prophylactic antibiotics in patients with recurrent infections + severe immunoparesis (though this is more commonly applied in MM/SMM)
4. Osteoporosis and Fractures
MGUS patients have a 2–3× increased risk of fracture (particularly vertebral and hip) compared to age-matched controls, even in the absence of lytic bone lesions. Why?
- Low-level osteoclast activation: Even a small clone produces cytokines (RANKL, DKK1, MIP-1α) that tip the bone remodelling balance toward resorption — not enough to cause lytic lesions, but enough to reduce BMD over years
- Inhibition of osteoblasts: DKK1 (Dickkopf-1) produced by clonal plasma cells inhibits the Wnt signalling pathway that drives osteoblast differentiation → reduced bone formation
- Age-related synergy: MGUS patients are elderly (median age 65–70) → already at risk for osteoporosis; the clonal contribution adds to this
- Immunoparesis-related inflammation: chronic low-grade immune dysregulation → pro-inflammatory state → bone loss
- Vertebral compression fractures
- Hip fractures
- Pathological fractures (these should raise suspicion for progression to MM with lytic lesions — differentiate carefully)
- DXA scan for baseline BMD
- Vitamin D and calcium supplementation
- Bisphosphonates or denosumab if osteoporosis is confirmed by standard criteria (but NOT routine for MGUS alone without osteoporosis)
5. Venous Thromboembolism (VTE)
MGUS patients have approximately a 2× increased risk of DVT and PE. Several mechanisms contribute:
- Paraprotein-mediated coagulation activation: M-proteins can interact with coagulation factors (e.g., acquired activated protein C resistance, anti-phospholipid antibody-like activity)
- Endothelial dysfunction: low-level cytokine production from clonal cells → endothelial activation → prothrombotic state
- Hyperviscosity (mild): even modest M-protein levels can slightly increase serum viscosity, slowing blood flow
- Inflammatory milieu: chronic immune dysregulation → acute phase reactant elevation → procoagulant shift
- DVT (lower limbs)
- Pulmonary embolism
- Risk is present throughout the course of MGUS, not just at diagnosis
- No routine anticoagulation for MGUS (risk too low)
- Appropriate VTE prophylaxis during hospitalisation, post-surgery, and periods of immobility
- Patient education on VTE warning signs
6. Peripheral Neuropathy
Peripheral neuropathy occurs in approximately 5% of MGUS patients, and is most strongly associated with IgM MGUS.
The predominant mechanism in IgM MGUS is:
- The IgM M-protein acts as an autoantibody against myelin-associated glycoprotein (MAG) — a protein on the surface of Schwann cells and myelin sheaths
- Anti-MAG antibody binding → complement activation → demyelination → distal sensorimotor polyneuropathy
- The neuropathy is typically slowly progressive, affecting distal lower limbs first, with prominent sensory ataxia and tremor
In non-IgM MGUS, neuropathy is less common and may involve:
- Light chain deposition in vasa nervorum or endoneurium
- Amyloid neuropathy (AL amyloidosis — see above)
- POEMS-related neuropathy (associated with λ light chain)
- Distal sensory loss (numbness, tingling, "glove and stocking")
- Gait ataxia (loss of proprioception)
- Weakness (later stages)
- Autonomic dysfunction (if amyloid-related)
- IgM anti-MAG neuropathy: rituximab (targets the IgM-producing B-cell/lymphoplasmacytic clone)
- Amyloid neuropathy: treat the underlying clone
- Symptomatic: gabapentin/pregabalin for neuropathic pain
"Myeloma (CRAB), Monoclonal gammopathy" is listed as a cause of CKD [4]
Pathophysiology
Even at MGUS-level tumour burden, the monoclonal protein can cause a spectrum of renal pathology — now termed Monoclonal Gammopathy of Renal Significance (MGRS):
| Renal Lesion | Mechanism | Key Features |
|---|---|---|
| AL amyloidosis | Light chains misfold → amyloid fibrils deposit in glomeruli | Nephrotic syndrome, Congo red positive |
| Light chain deposition disease (LCDD) | Light chains deposit in basement membranes as granular, non-fibrillar deposits | Nodular glomerulosclerosis (mimics diabetic nephropathy), Congo red NEGATIVE |
| Light chain proximal tubulopathy | Light chains are toxic to proximal tubular cells → acquired Fanconi syndrome | Glycosuria, aminoaciduria, phosphaturia, low-molecular-weight proteinuria |
| Type I cryoglobulinaemic GN | Monoclonal Ig precipitates in cold → immune complex GN | Purpura, arthralgias, GN |
| Proliferative GN with monoclonal Ig deposits | Monoclonal Ig deposited in glomeruli triggering proliferative response | Haematuria, proteinuria, ↓ complement |
| C3 glomerulopathy | Monoclonal Ig acts as autoantibody against complement regulators (e.g., Factor H) | C3 deposits without Ig deposits |
"Other renal diseases associated with monoclonal light chains: Amyloidosis (AL type), Light chain deposition disease, Light chain proximal tubulopathy, Type I cryoglobulinaemic glomerulonephritis" [12]
"Light and heavy chain deposition disease — complication of monoclonal gammopathy" [11]
MGRS — Why It Matters Clinically
If a patient labelled as "MGUS" develops unexplained proteinuria, haematuria, or rising creatinine, you must consider MGRS. The critical distinction: in true MGUS, the kidneys are normal. In MGRS, the clone is small but the protein is directly injuring the kidney. Renal biopsy is essential for diagnosis. Treatment is clone-directed (e.g., bortezomib-based), not just renal supportive care. Failure to recognise MGRS leads to progressive, irreversible renal damage.
This is not a "complication" in the traditional sense, but it is a clinically important consequence of having a circulating M-protein that can lead to misdiagnosis and inappropriate management.
"Laboratory artifacts: circulating M protein may interfere with other lab tests, e.g. spuriously low HDL-C level, high bilirubin level, altered inorganic phosphate level" [2]
| Lab Test Affected | Direction of Error | Mechanism |
|---|---|---|
| Total calcium | Falsely ↑ | "Apparent high Ca → due to high globulin; Ig may precipitate with PO₄, interfering with measurement" [6]. M-protein binds calcium → ↑ total Ca with normal ionised Ca |
| Inorganic phosphate | Variable | "Ig may precipitate with PO₄, interfering with measurement" [6] |
| HDL-cholesterol | Falsely ↓ | M-protein interferes with homogeneous HDL-C assays |
| Bilirubin | Falsely ↑ | Turbidity from high protein levels interferes with colorimetric assays |
| ESR | Markedly ↑ | Rouleaux formation accelerates RBC sedimentation |
| Anion gap | Altered | IgG is cationic → ↓ anion gap; IgA may → ↑ anion gap |
Clinical impact: Clinicians unfamiliar with these artifacts may launch unnecessary investigations (e.g., workup for hypercalcaemia, lipid abnormalities) when the results are simply interference from the paraprotein. Always check ionised calcium and consider M-protein interference when interpreting unusual biochemistry in MGUS patients.
Occasionally, MGUS is associated with dermatological conditions:
- Scleromyxoedema (papular mucinosis): IgG λ MGUS associated with diffuse papular skin thickening from dermal mucin deposition
- Pyoderma gangrenosum: associated with IgA MGUS
- Xanthoma (plane xanthogranuloma): especially with IgG M-protein
- Schnitzler syndrome: chronic urticarial rash + IgM MGUS + intermittent fever + bone/joint pain; rare but recognisable
- IgG Lambda monoclonal gammopathy associated with skin lesions has been illustrated in dermatology teaching material [21]
An underappreciated but real complication:
- Being told you have a "pre-cancer" can cause significant anxiety and psychological distress
- Patients may experience health anxiety, fear of progression at every follow-up visit, and depression
- Proper counselling and reassurance at diagnosis is essential (as discussed in the management section)
| Complication | Frequency | Mechanism | Key Clinical Feature |
|---|---|---|---|
| Malignant transformation | ~1%/year (overall) | Accumulation of genetic hits → SMM → MM/WM/lymphoma | Rising M-protein, new CRAB features |
| AL amyloidosis | Uncommon but lethal | Light chain misfolding → amyloid fibril organ deposition | Cardiomyopathy, nephrotic syndrome, neuropathy, macroglossia |
| Infections | ↑ 2× vs controls | Immunoparesis → ↓ normal Ig → ↓ opsonisation | Recurrent bacterial infections (encapsulated organisms) |
| Osteoporosis/Fractures | ↑ 2–3× vs controls | Low-level osteoclast activation + DKK1 osteoblast inhibition | Vertebral compression, hip fractures |
| VTE (DVT/PE) | ↑ ~2× vs controls | Paraprotein-mediated coagulopathy, endothelial dysfunction | DVT, PE |
| Peripheral neuropathy | ~5% | Anti-MAG antibodies (IgM MGUS); amyloid deposition; POEMS | Distal sensorimotor, ataxia |
| MGRS (renal) | Uncommon | M-protein/light chains directly damage kidney | Proteinuria, ↓ eGFR, various GN patterns |
| Lab interference | Common | M-protein interferes with biochemical assays | Factitious ↑Ca, ↓HDL, ↑bilirubin, altered anion gap |
| Skin disorders | Rare | Paraprotein deposition, immune-mediated | Scleromyxoedema, Schnitzler syndrome |
| Psychological distress | Common | Anxiety from "pre-cancer" label | Health anxiety, depression |
High Yield Summary — Complications of MGUS
- Malignant transformation is the most important complication: ~1% per year for non-IgM MGUS, ~2% per year for IgM MGUS [2][3]. Risk factors: size, type, FLC ratio, rate of rise of paraprotein, and BM morphology [1].
- "AL amyloidosis is a DDx if patient has suggestive symptoms" [1] — can occur with an MGUS-level clone and is fatal if untreated (especially cardiac AL).
- Immunoparesis causes increased susceptibility to encapsulated organisms — due to ↓ opsonization [16]. Vaccinations are recommended.
- Osteoporosis and fractures are 2–3× more common even without lytic bone lesions — due to low-level osteoclast activation and DKK1-mediated osteoblast inhibition.
- VTE risk is ~2× increased — paraprotein-mediated coagulopathy; no routine anticoagulation but ensure adequate peri-operative prophylaxis.
- MGRS: small clone but direct renal toxicity from M-protein/light chains. Must biopsy kidney; requires clone-directed treatment.
- Lab interference is common and clinically important: factitious hypercalcaemia (↑ total Ca, normal ionised Ca), spuriously low HDL-C, altered phosphate, high bilirubin [2][6]. Always check ionised calcium.
- Past paper tested: MGUS has 1% per year risk of progression (not 10% — that is SMM) [20].
Active Recall - Complications of MGUS
References
[1] Lecture slides: GC 030. An old man with bone pain and anaemia.pdf (MGUS slide) [2] Senior notes: Ryan Ho Haemtology.pdf (Section 3.6.2 Monoclonal Gammopathy of Undetermined Significance) [3] Senior notes: Block A - An old man with bone pain and anaemia_ multiple myeloma; monoclonal gammopathy.pdf (Development of myeloma / MGUS section) [4] Senior notes: Block A - Chronic Kidney Disease and its Complications.pdf (Causes of CKD) [5] Senior notes: Maksim Medicine Notes.pdf (Multiple myeloma clinical features, complications, immunoparesis) [6] Senior notes: Ryan Ho Chemical Path.pdf (Paraproteinaemia and factitious hypercalcaemia) [7] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (Spectrum of diseases for monoclonal gammopathy) [11] Senior notes: Block A – Nephrology Data Interpretation.pdf (Light and heavy chain deposition disease) [12] Senior notes: Block A - Nephrotology Teaching Clinic RTD.pdf (Renal diseases associated with monoclonal light chains) [16] Senior notes: Ryan Ho Haemtology.pdf (MM laboratory findings, immunoparesis mechanism) [18] Senior notes: Block A - Hematology Data Interpretation.pdf (Congo red stain, electron microscopy for amyloidosis) [20] Past papers: 2023 Fourth Summative MCQ.pdf (Question 44) [21] Lecture slides: Derm General Clerkship 2026 Part2.pdf (IgG Lambda monoclonal gammopathy with skin lesion)
High Yield Summary
- MGUS is the most common plasma cell dyscrasia — ~5% of people > 50 years; M > F; prevalence ↑ with age
- Definition: M-protein < 3 g/dL, BM plasma cells < 10%, no B-cell lymphoproliferative disorder, no end-organ damage (CRAB)
- Three main subtypes: Non-IgM MGUS (most common, IgG > IgA), IgM MGUS (risk of WM/lymphoma), LC-MGUS
- Progression risk: Non-IgM ~0.8%/year, IgM ~2%/year, LC ~0.3%/year
- Risk factors for progression: Size of M-protein, type (non-IgG worse), abnormal FLC ratio, rate of rise, BM morphology
- By definition asymptomatic — always an incidental finding; any CRAB symptom = exclude myeloma
- Most important DDx to exclude: AL amyloidosis (especially if suggestive symptoms), MM, WM
- Lab artifacts: Elevated ESR, reversed A:G ratio, factitious hypercalcaemia (check ionised Ca), interference with HDL-C, phosphate, bilirubin assays
- Management: Monitoring only — no treatment; regular follow-up to detect progression
- MGRS is a newer concept where the small clone causes direct renal damage → requires treatment despite not meeting MM criteria
High Yield Summary — Differential Diagnosis of MGUS
- MGUS is a diagnosis of exclusion — you must systematically rule out MM, SMM, AL amyloidosis, WM, LCDD, POEMS, lymphoma/CLL, and MGRS before labelling a monoclonal gammopathy as "undetermined significance."
- AL amyloidosis is the most important DDx if the patient has suggestive symptoms [1] — even with a small clone, light chains can cause fatal organ damage.
- The distinction between MGUS, SMM, and MM is based on three parameters: M-protein level, BM plasma cell percentage, and presence of CRAB/MDE.
- IgM MGUS is a distinct entity — the differential includes WM, NHL, and CLL (lymphoproliferative rather than plasma cell lineage).
- The monoclonal gammopathy DDx table by isotype [7]: Non-IgM MGUS → SMM → MM; IgM MGUS → Smouldering WM → WM; LC-MGUS → Idiopathic Bence Jones proteinuria → LC-MM.
- If a small clone causes organ damage (renal, cardiac, neurological), it is not MGUS — consider MGRS, AL amyloidosis, or LCDD.
- An altered anion gap (reduced in IgG, increased in IgA gammopathy) can be a laboratory clue to underlying paraproteinaemia.
High Yield Summary — Diagnostic Criteria, Algorithm, and Investigations
- MGUS diagnostic criteria (all must be met): M-protein < 3 g/dL; BM plasma cells < 10%; no B-cell lymphoproliferative disorder; no end-organ damage (CRAB/SLiM) [1]
- CRAB = Calcium ↑, Renal insufficiency, Anaemia, Bone lesions. SLiM = Sixty % BM PC, Light chain ratio > 100, MRI > 1 focal lesion. Any CRAB or SLiM = active MM, not MGUS [5]
- Investigation trio for monoclonal gammopathy screening: SPEP with immunofixation + serum FLC + 24h urine for BJP [5]
- SPEP patterns: Normal / Pan-immunoparesis / Polyclonal ↑ (reactive, do NOT refer to haematology) / M-spike ± immunoparesis [15]
- Normal κ:λ ratio = 0.26–1.65; abnormal suggests monoclonal origin [5]
- BM biopsy is definitive: confirms < 10% clonal PC, provides morphology, immunophenotyping (CD138, light chain restriction), and cytogenetics for risk stratification
- Skeletal imaging (WB low-dose CT preferred) must be normal in MGUS; ALP is usually normal in myeloma because osteoblastic activity is preserved [5]
- Risk stratification: Mayo Clinic model uses M-protein ≥ 1.5, non-IgG isotype, abnormal FLC ratio → 0–3 risk factors determining surveillance intensity
- Always exclude AL amyloidosis if any suggestive symptoms — even a small clone can produce lethal amyloid deposits [1]
- Factitious hypercalcaemia: paraprotein binds calcium → ↑ total Ca with normal ionised Ca; check ionised Ca [6]
High Yield Summary — MGUS Management
- "Management: monitoring only" [2] — no chemotherapy, no immunotherapy for MGUS itself.
- "Only multiple myeloma patients will be symptomatic with organ involvement → requires treatment. Other forms do not require treatment → require monitoring." [3]
- Risk stratification uses the Mayo Clinic 3-factor model: M-protein ≥ 1.5 g/dL, non-IgG isotype, abnormal sFLC ratio.
- Surveillance: SPEP, sFLC ratio, CBC, calcium, creatinine — at 6 months, then annually or 2–3 yearly depending on risk group.
- Rate of rise in paraprotein is a key monitoring parameter [1][3] — a rapid rise warrants expedited workup including BM biopsy and imaging.
- Associated risk management: bone health (DXA, Vit D), infection prevention (vaccinations), VTE awareness.
- Exceptions where clone-directed treatment IS indicated despite MGUS-level tumour burden: MGRS (renal damage from M-protein), AL amyloidosis (organ deposition), and IgM MGUS with symptomatic anti-MAG neuropathy.
- If MGUS progresses to active MM: triple therapy (proteasome inhibitor + IMiD + dexamethasone) ± autologous HSCT [5].
- Bisphosphonates are NOT routinely used in MGUS — only if coexisting osteoporosis. For patients with CKD (eGFR < 35): denosumab instead of IV bisphosphonates [19].
- Patient education is crucial: reassure (not cancer), explain monitoring plan, and teach red-flag symptoms for urgent return.
High Yield Summary — Complications of MGUS
- Malignant transformation is the most important complication: ~1% per year for non-IgM MGUS, ~2% per year for IgM MGUS [2][3]. Risk factors: size, type, FLC ratio, rate of rise of paraprotein, and BM morphology [1].
- "AL amyloidosis is a DDx if patient has suggestive symptoms" [1] — can occur with an MGUS-level clone and is fatal if untreated (especially cardiac AL).
- Immunoparesis causes increased susceptibility to encapsulated organisms — due to ↓ opsonization [16]. Vaccinations are recommended.
- Osteoporosis and fractures are 2–3× more common even without lytic bone lesions — due to low-level osteoclast activation and DKK1-mediated osteoblast inhibition.
- VTE risk is ~2× increased — paraprotein-mediated coagulopathy; no routine anticoagulation but ensure adequate peri-operative prophylaxis.
- MGRS: small clone but direct renal toxicity from M-protein/light chains. Must biopsy kidney; requires clone-directed treatment.
- Lab interference is common and clinically important: factitious hypercalcaemia (↑ total Ca, normal ionised Ca), spuriously low HDL-C, altered phosphate, high bilirubin [2][6]. Always check ionised calcium.
- Past paper tested: MGUS has 1% per year risk of progression (not 10% — that is SMM) [20].